Damora Therapeutics (DMRA) Cash & Equivalents (2019 - 2026)

Damora Therapeutics has reported Cash & Equivalents for 8 years, with the latest figure at $202.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 1595.25% year-over-year to $202.4 million; the trailing twelve-month figure through Mar 2026 stood at $202.4 million (up 1595.25% YoY), and the FY2025 full-year result was $257.6 million, up 1717.45% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $202.4 million, down from $257.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $257.6 million in Q4 2025, with the low at $7.6 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $47.2 million across 5 years, with a median of $25.1 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 77.83% — and 2025, when it jumped 1717.45%.
• Damora Therapeutics' Cash & Equivalents stood at $32.8 million in 2022, then dropped by 22.85% to $25.3 million in 2023, then plunged by 43.96% to $14.2 million in 2024, then jumped by 1717.45% to $257.6 million in 2025, then declined by 21.44% to $202.4 million in 2026.
• The last three Cash & Equivalents figures came in at $202.4 million (Q1 2026), $257.6 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.